<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972152</url>
  </required_header>
  <id_info>
    <org_study_id>XSGP-201</org_study_id>
    <secondary_id>2R44DK085809-02</secondary_id>
    <nct_id>NCT01972152</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia</brief_title>
  <official_title>A RANDOMIZED, PHASE 2, DOUBLE-BLIND, 3-WAY CROSSOVER STUDY WITH G-PEN™ (GLUCAGON INJECTION) TO EVALUATE SAFETY, TOLERABILITY AND COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS TO LILLY GLUCAGON™ (GLUCAGON FOR INJECTION [rDNA ORIGIN]) IN HEALTHY VOLUNTEERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emissary International LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly
      Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a
      complication of diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To Evaluate the Safety and Tolerability of G-Pen™ (Glucagon Injection) 1
      mg

      Secondary objective (1): To Evaluate the pharmacodynamics (Efficacy) of G-Pen™ (Glucagon
      Injection) 1 mg

      Secondary objective (2):To compare the pharmacokinetics of G-Pen™ (glucagon injection) 1mg
      [test] administered as 0.5 mg and 1 mg injections, versus Lilly Glucagon™ (glucagon for
      injection [rDNA origin]) 1 mg (reference)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>From first dose until completion of the post-treatment follow-up visit, up to 6 weeks</time_frame>
    <description>Number of serious adverse events (SAEs) per treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Area Under the Curve (AUC)</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Glucose area under the curve from baseline to 240 minutes post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Cmax</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Tmax</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Time to Maximum Glucose Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose AUCex</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Area Under the Glucose Excursion Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose MAE</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Maximum absolute glucose excursion from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Tex</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Earliest reported time of MAE, based on within-subject changes from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon AUC</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Glucagon area under the curve from baseline to 240 minutes post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Cmax</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Tmax</measure>
    <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Time to maximum concentration of glucagon</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>G-Pen(TM) 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-Pen(TM) 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lilly Glucagon(TM) 1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen(TM) 1 mg</intervention_name>
    <arm_group_label>G-Pen(TM) 1 mg</arm_group_label>
    <arm_group_label>G-Pen(TM) 0.5 mg</arm_group_label>
    <arm_group_label>Lilly Glucagon(TM) 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lilly Glucagon(TM) 1 mg</intervention_name>
    <arm_group_label>G-Pen(TM) 1 mg</arm_group_label>
    <arm_group_label>G-Pen(TM) 0.5 mg</arm_group_label>
    <arm_group_label>Lilly Glucagon(TM) 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen(TM) 0.5 mg</intervention_name>
    <arm_group_label>G-Pen(TM) 1 mg</arm_group_label>
    <arm_group_label>G-Pen(TM) 0.5 mg</arm_group_label>
    <arm_group_label>Lilly Glucagon(TM) 1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects between the ages of 18 and 60 years of age, inclusive,
             at Screening.

          2. Women must be of non-childbearing potential as defined by one of the following:

               -  Females who are &gt;45 and &lt; 60 years of age at Screening and amenorrheic for at
                  least 2 years

               -  Females who have had a documented hysterectomy and/or bilateral oophorectomy.

          3. Females of childbearing potential with a negative pregnancy test at Screening and
             Treatment visits, using one of the following forms of contraception for the duration
             of participation in the study (i.e., until Follow-up 7-14 days post last dose):

               -  Oral contraceptive

               -  Injectable progesterone

               -  Subdermal implant

               -  Spermicidal foam/gel/film/cream/suppository

               -  Diaphragm with spermicide

               -  Copper or hormonal containing intrauterine device (IUD)

               -  Sterile male partner vasectomized &gt; 6 month pre-dosing.

          4. Male subjects are required to use a condom and one of the methods of contraception in
             2. or 3. above starting at Randomization and for the duration of the study.

          5. Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

          6. Subjects must be willing and able to comply with scheduled visits, treatment,
             laboratory tests and study procedures.

        Exclusion Criteria:

          1. Recent (i.e., within three (3) months prior to Screening) evidence or medical history
             of unstable concurrent disease such as: documented evidence or history of clinically
             significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular,
             hepatic, psychiatric, immunological, or clinically significant neurological disease.

          2. Mean of triplicate set of seated BP readings at Screening, confirmed by 1 set of
             triplicate at Screening, if deemed necessary where systolic blood pressure (SBP) &lt;90
             or &gt;140 mm Hg, and diastolic blood pressure (DBP) &lt;50 or &gt;90 mm Hg.

          3. Cardiovascular event within 6 months prior to screening such as unstable angina, acute
             coronary syndrome, myocardial infarction, therapeutic coronary procedure (e.g., stent
             placement, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery
             By-pass Grafting (CABG)), stroke or transient ischemic attack.

          4. Clinically significant ECG abnormalities.

          5. Study participants who are pregnant at Screening are not eligible for this study.

          6. Breast feeding must be discontinued if a subject wishes to participate in this study.

          7. Positive test for hepatitis B, hepatitis C, or HIV found at Screening.

          8. Positive urine drug test for illicit drugs at Screening.

          9. Allergies to glucagon, glucagon-like products or to any of the excipients in the
             investigational formulation.

         10. Recent (i.e., within three (3) months prior to Screening) administration of glucagon.

         11. Any prior cerebrovascular accident or major permanent neurological damage such as
             aphasia, hemiparesis, or dementia.

         12. Peripheral artery disease with uncontrolled claudication

         13. Current diagnosis or current clinical evidence of any New York Heart Association
             classification of heart failure.

         14. Subjects with any of the following abnormalities in clinical laboratory tests at
             Screening, confirmed by a single repeat, if necessary:

               -  Total bilirubin &gt; 1.5x upper limit of normal (ULN)

               -  aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥
                  2.5x ULN.

               -  Creatinine &gt; 2.5x ULN.

         15. History of regular alcohol consumption as defined by alcohol intake in a quantity
             exceeding 7 drinks per week for females or 14 drinks per week for males, where 1 drink
             = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of
             hard liquor.

         16. Participation in other studies involving administration of an investigational drug or
             device within 30 days or 5 half-lives, whichever is longer, before screening for the
             current study and during participation in the current study.

         17. Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to Screening.

         18. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Diabetes Institute, University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Diabetes Institute, University Health System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <results_first_submitted>November 20, 2015</results_first_submitted>
  <results_first_submitted_qc>January 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study involved healthy volunteers who were recruited from the local community surrounding a state-affiliated diabetes treatment center over a period of 3 months.</recruitment_details>
      <pre_assignment_details>Of a total of 41 individuals recruited, 4 declined participation, 7 did not meet eligibility criteria and 30 were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-Pen(TM) 0.5 mg First, Then G-Pen(TM) 1 mg, Then Lilly 1 mg</title>
          <description>G-Pen(TM) (glucagon injection), single 0.5 mg subcutaneous (SC) injection at treatment visit 1 followed by a 3-14 day washout, G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection at treatment visit 2 followed by a 3-14 day washout, Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection at treatment visit 3.</description>
        </group>
        <group group_id="P2">
          <title>G-Pen(TM) 0.5 mg First, Then Lilly 1 mg, Then G-Pen(TM) 1 mg</title>
          <description>G-Pen(TM) (glucagon injection), single 0.5 mg subcutaneous (SC) injection at treatment visit 1 followed by a 3-14 day washout, Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection at treatment visit 2, G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection at treatment visit 3.</description>
        </group>
        <group group_id="P3">
          <title>G-Pen(TM) 1 mg First, Then G-Pen(TM) 0.5 mg , Then Lilly 1 mg</title>
          <description>G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection at treatment visit 1 followed by a 3-14 day washout, G-Pen(TM) (glucagon injection), single 0.5 mg SC injection at treatment visit 2 followed by a 3-14 day washout, Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection at treatment visit 3.</description>
        </group>
        <group group_id="P4">
          <title>G-Pen(TM) 1 mg First, Then Lilly 1 mg, Then G-Pen(TM) 0.5 mg</title>
          <description>G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection at treatment visit 1 followed by a 3-14 day washout, Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection of at treatment visit 2 followed by a 3-14 day washout, G-Pen(TM) (glucagon injection), single 0.5 mg SC injection at treatment visit 3.</description>
        </group>
        <group group_id="P5">
          <title>Lilly 1 mg First, Then G-Pen(TM) 0.5 mg, Then G-Pen(TM) 1 mg</title>
          <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection at treatment visit 1 followed by a 3-14 day washout, G-Pen(TM) (glucagon injection), single 0.5 mg subcutaneous (SC) injection at treatment visit 2 followed by a 3-14 day washout, G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection at treatment visit 3.</description>
        </group>
        <group group_id="P6">
          <title>Lilly 1 mg First, Then G-Pen(TM) 1 mg, Then G-Pen(TM) 0.5 mg</title>
          <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection at treatment visit 1 followed by a 3-14 day washout, G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection at treatment visit 2 followed by a 3-14 day washout, G-Pen(TM) (glucagon injection), single 0.5 mg subcutaneous (SC) injection at treatment visit 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Treatment Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Treatment Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study involved a 3-way cross-over design with 30 total randomized subjects, so the baseline characteristics are the same for all 3 arms.</population>
      <group_list>
        <group group_id="B1">
          <title>Total Study Group</title>
          <description>Includes all 30 randomized subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events</title>
        <description>Number of serious adverse events (SAEs) per treatment group</description>
        <time_frame>From first dose until completion of the post-treatment follow-up visit, up to 6 weeks</time_frame>
        <population>All subjects receiving treatment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection
G-Pen(TM) 1 mg
Lilly Glucagon(TM) 1 mg
G-Pen(TM) 0.5 mg</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
G-Pen(TM) 1 mg
Lilly Glucagon(TM) 1 mg
G-Pen(TM) 0.5 mg</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
G-Pen(TM) 1 mg
Lilly Glucagon(TM) 1 mg
G-Pen(TM) 0.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Number of serious adverse events (SAEs) per treatment group</description>
          <population>All subjects receiving treatment were included in this analysis.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Area Under the Curve (AUC)</title>
        <description>Pharmacodynamic parameter: Glucose area under the curve from baseline to 240 minutes post-treatment</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Area Under the Curve (AUC)</title>
          <description>Pharmacodynamic parameter: Glucose area under the curve from baseline to 240 minutes post-treatment</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>min*mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.1" spread="64.9"/>
                    <measurement group_id="O2" value="467" spread="47.9"/>
                    <measurement group_id="O3" value="473.5" spread="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Data were log transformed for analysis.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Cmax</title>
        <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Cmax</title>
          <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.04" spread="24.94"/>
                    <measurement group_id="O2" value="140.32" spread="23.59"/>
                    <measurement group_id="O3" value="154.9" spread="28.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>Data were log transformed for analysis.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Data were log transformed for analysis.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tmax</title>
        <description>Pharmacodynamic parameter: Time to Maximum Glucose Concentration</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tmax</title>
          <description>Pharmacodynamic parameter: Time to Maximum Glucose Concentration</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="11.8"/>
                    <measurement group_id="O2" value="44.5" spread="11.2"/>
                    <measurement group_id="O3" value="46.5" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose AUCex</title>
        <description>Pharmacodynamic parameter: Area Under the Glucose Excursion Curve</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose AUCex</title>
          <description>Pharmacodynamic parameter: Area Under the Glucose Excursion Curve</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>min*mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.5" spread="89.1"/>
                    <measurement group_id="O2" value="197.3" spread="74.7"/>
                    <measurement group_id="O3" value="223" spread="101.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose MAE</title>
        <description>Pharmacodynamic parameter: Maximum absolute glucose excursion from baseline</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose MAE</title>
          <description>Pharmacodynamic parameter: Maximum absolute glucose excursion from baseline</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="22"/>
                    <measurement group_id="O2" value="42.5" spread="19.8"/>
                    <measurement group_id="O3" value="53.2" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tex</title>
        <description>Pharmacodynamic parameter: Earliest reported time of MAE, based on within-subject changes from baseline</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tex</title>
          <description>Pharmacodynamic parameter: Earliest reported time of MAE, based on within-subject changes from baseline</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="11.8"/>
                    <measurement group_id="O2" value="61.6" spread="52.3"/>
                    <measurement group_id="O3" value="68.8" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Data were log transformed for analysis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon AUC</title>
        <description>Pharmacokinetic parameter: Glucagon area under the curve from baseline to 240 minutes post-treatment</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon AUC</title>
          <description>Pharmacokinetic parameter: Glucagon area under the curve from baseline to 240 minutes post-treatment</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>min*pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3259.9" spread="3447.5"/>
                    <measurement group_id="O2" value="2105.3" spread="2381.9"/>
                    <measurement group_id="O3" value="4781.7" spread="2222.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Data were log transformed for analysis</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Data were log transformed for analysis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Cmax</title>
        <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Cmax</title>
          <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2055.4" spread="2052"/>
                    <measurement group_id="O2" value="1318.8" spread="1435.8"/>
                    <measurement group_id="O3" value="4429.9" spread="3970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Data were log transformed for analysis</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Data were log transformed for analysis.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Tmax</title>
        <description>Pharmacokinetic parameter: Time to maximum concentration of glucagon</description>
        <time_frame>Approximately 15 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 240 minutes post-injection</time_frame>
        <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen(TM) 1 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection</description>
          </group>
          <group group_id="O2">
            <title>G-Pen(TM) 0.5 mg</title>
            <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection</description>
          </group>
          <group group_id="O3">
            <title>Lilly Glucagon(TM) 1 mg</title>
            <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Tmax</title>
          <description>Pharmacokinetic parameter: Time to maximum concentration of glucagon</description>
          <population>Per protocol analysis set. Two subjects were excluded from all analyses: one who completed no treatment visits and had no evaluable data and another who violated eligibility criteria. A third subject was excluded from analysis for the one treatment visit at which the subject's blood samples were inadvertently diluted with saline during collection.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="15.2"/>
                    <measurement group_id="O2" value="33.3" spread="13.2"/>
                    <measurement group_id="O3" value="18.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the first administration of study drug to an untreated follow-up visit occurring 7-14 days after the last treatment, up to 6 weeks.</time_frame>
      <desc>Adverse events are reported by Preferred Term</desc>
      <group_list>
        <group group_id="E1">
          <title>G-Pen(TM) 1 mg</title>
          <description>G-Pen(TM) (glucagon injection), single 1 mg SC injection
G-Pen(TM) 1 mg
Lilly Glucagon(TM) 1 mg
G-Pen(TM) 0.5 mg</description>
        </group>
        <group group_id="E2">
          <title>G-Pen(TM) 0.5 mg</title>
          <description>G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
G-Pen(TM) 1 mg
Lilly Glucagon(TM) 1 mg
G-Pen(TM) 0.5 mg</description>
        </group>
        <group group_id="E3">
          <title>Lilly Glucagon(TM) 1 mg</title>
          <description>Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
G-Pen(TM) 1 mg
Lilly Glucagon(TM) 1 mg
G-Pen(TM) 0.5 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (5.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hot Flushes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="28"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin J. Cummins, VP, Drug Development</name_or_title>
      <organization>Xeris Pharmaceuticals, Inc.</organization>
      <phone>512-498-2675</phone>
      <email>mcummins@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

